GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGUANGZHOU,China and MOSCOW, Russia ---(Businesswire)--- Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and a pipeline ofbiosimilars, today announced the company has reached licensing and supply agreements with Pharmapa...
GUANGZHOU, China, September 27,2021 (BUSINESSWIRE) –Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”)and Intract Pharma (“Intract”) announced a global collaboration and licensingagreement that gives Bio-Thera access to Intract’s Soteria® and Phloral® drugdelivery technologies to devel...
GUANGZHOU, China, September 8, 2021 (BUSINESSWIRE) --Bio-Thera Solutions, Ltd. (688177.SH) today announced that it has entered into a commercialization and license agreement with Sandoz to commercialize BAT1706, an anti- vascular endothelial growth factor (VEGF) monoclonal antibody that is a propose...
